In the seminar, President of TSH Biopharm Mr Yang shared how the company has accelerated the integration of clinical therapies within a short period of time, and delivered 16 Asian registration cases and successfully handled 2 patent linkage cases.

In the seminar, Yang pointed out that in the biomedical field, the amount of licensing transactions has always been a hot topic, but the so-called licensing access is actually a series of processes that allow a pharmaceutical product to go from pre-clinical, clinical trials, testing and registration to licensing. If one piece of the puzzle is missing, the whole case may fail or be launched later than the competition, which will significantly affect the valuation and investment recovery. Therefore, the question of which partners to use throughout the process, or which strategies to accelerate the launch of a product to support a clinical unmet need, is a very important one.

In the past three and a half years, TSH has been implementing a dual-engine strategy, which Yang emphasises is an alliance approach to get products to market quickly. The company is located in Asia, Europe, USA, Korea, Taiwan and Southeast Asia.

This has enabled us to deliver 16 Asian registrations and handle 2 patent-linked cases within a very short period of time. 3 cases have already been granted Taiwan drug certificates and 1 case has been granted health insurance coverage and will be effective for clinical use tomorrow (1 November).

Although the number of deals has decreased slightly in recent years due to the COVID-19 epidemic, the value of deals has remained stable, indicating that companies with capital in hand and a flexible strategy still have a good chance of securing the products they want. The key to this, according to Yeoh, is how to make the whole transaction a fast, optimised process, which will give you the advantage of getting your product to market quickly.

There are several steps here: sourcing, signing a confidentiality agreement, setting up the business structure, valuing the deal and signing it. However, as the number of early stage R&D cases continues to grow, the challenge is to estimate an appropriate and mutually agreeable value, where intellectual and legal professionals play an important role, as it is very relevant to the overall valuation and whether the patent can actually be owned and implemented. The success of the process depends on the skills of the parties involved at each stage, and the strategic aspects and execution of the process are a major test.

More information please visit tshbiopharm.com